• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

分子工程在基于 T 细胞的免疫疗法中的应用。

Applications of molecular engineering in T-cell-based immunotherapies.

机构信息

Department of Nanoengineering, University of California, San Diego, California.

Program in Chemical Engineering, University of California, San Diego, California.

出版信息

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019 Sep;11(5):e1557. doi: 10.1002/wnan.1557. Epub 2019 Apr 10.

DOI:10.1002/wnan.1557
PMID:30972976
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7869905/
Abstract

Harnessing an individual's immune cells to mediate antitumor and antiviral responses is a life-saving option for some patients with otherwise intractable forms of cancer and infectious disease. In particular, T-cell-based engineered immune cells are a powerful new class of therapeutics with remarkable efficacy. Clinical experience has helped to define some of the major challenges for reliable, safe, and effective deployment of T-cells against a broad range of diseases. While poised to revolutionize immunotherapy, scalable manufacturing, safety, specificity, and the development of resistance are potential roadblocks in their widespread usage. The development of molecular engineering tools to allow for the direct or indirect engineering of T-cells to enable one to troubleshoot delivery issues, amplify immunomodulatory effects, integrate the synergistic effects of different molecules, and home to the target cells in vivo. In this review, we will analyze thus-far developed cell- and material-based tools for enhancing T-cell therapies, including methods to improve safety and specificity, enhancing efficacy, and overcoming limitations in scalable manufacturing. We summarize the potential of T-cells as immune modulating therapies and the potential future directions for enabling their adoption for a broad range of diseases. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Nanotechnology Approaches to Biology > Cells at the Nanoscale.

摘要

利用个体的免疫细胞来介导抗肿瘤和抗病毒反应,是一些患有其他难以治疗的癌症和传染病患者的救命选择。特别是基于 T 细胞的工程免疫细胞是一类具有显著疗效的新型强大治疗药物。临床经验有助于确定针对广泛疾病可靠、安全和有效部署 T 细胞的一些主要挑战。虽然有望彻底改变免疫疗法,但可扩展性制造、安全性、特异性以及耐药性的发展是其广泛应用的潜在障碍。开发分子工程工具可以直接或间接对 T 细胞进行工程改造,从而解决传递问题,放大免疫调节作用,整合不同分子的协同作用,并在体内归巢到靶细胞。在这篇综述中,我们将分析迄今为止为增强 T 细胞疗法而开发的基于细胞和材料的工具,包括提高安全性和特异性、增强疗效以及克服可扩展性制造限制的方法。我们总结了 T 细胞作为免疫调节疗法的潜力,以及为广泛疾病采用它们的潜在未来方向。本文属于以下分类:

生物学中的纳米技术方法 > 生物学中的纳米尺度系统

治疗方法和药物发现 > 肿瘤疾病的纳米医学

生物学中的纳米技术方法 > 细胞的纳米尺度

相似文献

1
Applications of molecular engineering in T-cell-based immunotherapies.分子工程在基于 T 细胞的免疫疗法中的应用。
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019 Sep;11(5):e1557. doi: 10.1002/wnan.1557. Epub 2019 Apr 10.
2
T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance.基于 T 细胞受体的癌症免疫疗法:新兴的疗效和耐药途径。
Immunol Rev. 2019 Jul;290(1):127-147. doi: 10.1111/imr.12772.
3
Engineering Hematopoietic Cells for Cancer Immunotherapy: Strategies to Address Safety and Toxicity Concerns.工程化造血细胞用于癌症免疫治疗:解决安全性和毒性问题的策略。
J Immunother. 2016 Sep;39(7):249-59. doi: 10.1097/CJI.0000000000000134.
4
Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons.工程化 TCR-T 细胞免疫疗法在抗肿瘤精准医学中的利与弊。
Front Immunol. 2021 Mar 30;12:658753. doi: 10.3389/fimmu.2021.658753. eCollection 2021.
5
Genetic engineering of T cells for immunotherapy.T 细胞免疫疗法的基因工程。
Nat Rev Genet. 2021 Jul;22(7):427-447. doi: 10.1038/s41576-021-00329-9. Epub 2021 Feb 18.
6
Nanoinjection: A Platform for Innovation in Ex Vivo Cell Engineering.纳米注射:离体细胞工程创新平台。
Acc Chem Res. 2024 Jun 18;57(12):1722-1735. doi: 10.1021/acs.accounts.4c00190. Epub 2024 May 31.
7
Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies.寻找 CAR 的钥匙:鉴定用于 T 细胞重定向免疫疗法的新型靶标抗原。
Int J Mol Sci. 2020 Jan 14;21(2):515. doi: 10.3390/ijms21020515.
8
Current Advancements in Anti-Cancer Chimeric Antigen Receptor T Cell Immunotherapy and How Nanotechnology May Change the Game.当前癌症嵌合抗原受体 T 细胞免疫疗法的进展以及纳米技术如何改变游戏规则。
Int J Mol Sci. 2024 May 14;25(10):5361. doi: 10.3390/ijms25105361.
9
Immunobiology of chimeric antigen receptor T cells and novel designs.嵌合抗原受体 T 细胞的免疫生物学和新型设计。
Immunol Rev. 2019 Jul;290(1):100-113. doi: 10.1111/imr.12794.
10
Mechanical Immunoengineering of T cells for Therapeutic Applications.T 细胞的机械免疫工程用于治疗应用。
Acc Chem Res. 2020 Dec 15;53(12):2777-2790. doi: 10.1021/acs.accounts.0c00486. Epub 2020 Dec 1.

引用本文的文献

1
Nanodrug Delivery Systems in Antitumor Immunotherapy.抗肿瘤免疫治疗中的纳米药物递送系统
Biomater Res. 2024 Apr 25;28:0015. doi: 10.34133/bmr.0015. eCollection 2024.
2
Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment.嵌合抗原受体 T 细胞治疗后免疫效应细胞相关神经毒性综合征的机制。
WIREs Mech Dis. 2022 Nov;14(6):e1576. doi: 10.1002/wsbm.1576. Epub 2022 Jul 24.
3
Optimizing interleukin-2 concentration, seeding density and bead-to-cell ratio of T-cell expansion for adoptive immunotherapy.

本文引用的文献

1
Antigens reversibly conjugated to a polymeric glyco-adjuvant induce protective humoral and cellular immunity.抗原可逆地与聚合糖佐剂结合,诱导保护性体液和细胞免疫。
Nat Mater. 2019 Feb;18(2):175-185. doi: 10.1038/s41563-018-0256-5. Epub 2019 Jan 14.
2
Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers.人类肿瘤中肿瘤内 TCR 库的低反应性和变异性。
Nat Med. 2019 Jan;25(1):89-94. doi: 10.1038/s41591-018-0266-5. Epub 2018 Dec 3.
3
IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System.
优化细胞因子白细胞介素 2 浓度、接种密度和免疫细胞磁珠与细胞比例以用于过继性免疫治疗。
BMC Immunol. 2021 Jul 3;22(1):43. doi: 10.1186/s12865-021-00435-7.
4
Cancer microenvironment and genomics: evolution in process.癌症微环境与基因组学:进化中的进程。
Clin Exp Metastasis. 2022 Feb;39(1):85-99. doi: 10.1007/s10585-021-10097-9. Epub 2021 May 10.
5
Mass Spectrometry Advances and Perspectives for the Characterization of Emerging Adoptive Cell Therapies.质谱分析技术在新兴过继细胞疗法表征方面的进展与展望。
Molecules. 2020 Mar 19;25(6):1396. doi: 10.3390/molecules25061396.
为一项临床试验进行基因编程以建立持久的癌症靶向免疫系统的 IND 研究。
Clin Cancer Res. 2019 Feb 1;25(3):1000-1011. doi: 10.1158/1078-0432.CCR-18-0963. Epub 2018 Nov 8.
4
Efficient magnetic enrichment of antigen-specific T cells by engineering particle properties.通过工程化颗粒性质实现抗原特异性 T 细胞的高效磁富集。
Biomaterials. 2018 Dec;187:105-116. doi: 10.1016/j.biomaterials.2018.09.029. Epub 2018 Sep 28.
5
Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.针对独特和共享致癌基因的新抗原反应性 T 细胞的增强检测,用于个性化癌症免疫治疗。
JCI Insight. 2018 Oct 4;3(19):122467. doi: 10.1172/jci.insight.122467.
6
4-1BB enhancement of CAR T function requires NF-κB and TRAFs.4-1BB 增强 CAR T 功能需要 NF-κB 和 TRAFs。
JCI Insight. 2018 Sep 20;3(18). doi: 10.1172/jci.insight.121322.
7
Reprogramming human T cell function and specificity with non-viral genome targeting.利用非病毒基因组靶向技术重新编程人类 T 细胞的功能和特异性。
Nature. 2018 Jul;559(7714):405-409. doi: 10.1038/s41586-018-0326-5. Epub 2018 Jul 11.
8
Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery.通过 TCR 信号响应型纳米颗粒药物递送增强 T 细胞疗法。
Nat Biotechnol. 2018 Sep;36(8):707-716. doi: 10.1038/nbt.4181. Epub 2018 Jul 9.
9
Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer.免疫识别导致转移性乳腺癌完全持久消退的体细胞突变。
Nat Med. 2018 Jun;24(6):724-730. doi: 10.1038/s41591-018-0040-8. Epub 2018 Jun 4.
10
Chimeric antigen receptors that trigger phagocytosis.触发吞噬作用的嵌合抗原受体。
Elife. 2018 Jun 4;7:e36688. doi: 10.7554/eLife.36688.